Moderna, Inc. (0A45.IL)
| Previous close | 111.15 |
| Open | 111.62 |
| Bid | 109.18 x N/A |
| Ask | 114.76 x N/A |
| Day's range | 111.62 - 111.62 |
| 52-week range | 62.55 - 142.32 |
| Volume | |
| Avg. volume | 17,923 |
| Market cap | 54.269B |
| Beta (5Y monthly) | 1.64 |
| PE ratio (TTM) | 41.65 |
| EPS (TTM) | 2.68 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.We Think Shareholders May Want To Consider A Review Of Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation Package
Key Insights Moderna to hold its Annual General Meeting on 6th of May CEO Stephane Bancel's total compensation includes...
BenzingamRNA Is Promising A Breakthrough In Fighting Cancer
When it comes to cancer, there’s innovation both on the diagnostics and the treatment front thanks to messenger RNA, or mRNA, a genetic material we all got acquainted with during the COVID-19 era as it allowed pharmaceutical companies like Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) to develop their groundbreaking vaccines in record time. By the looks of it, this was only the beginning of the healthcare revolution that mRNA triggered. Mainz Biomed N.V. (NASDAQ: MYNZ) to revolutionize c
ZacksModerna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect
Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.
